Search - tctmd.com

Displaying 81 - 100 of 155

Sort: Relevancy | Date

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

L.A. McKeown

April 18, 2025

News Daily News

AHA Statement Zeroes In On Sleep Health

L.A. McKeown

April 17, 2025

News Daily News

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Yael L. Maxwell

April 16, 2025

News Daily News

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

L.A. McKeown

April 15, 2025

News Daily News

Cardiotoxicity Rare With Common GI Chemotherapy

L.A. McKeown

April 15, 2025

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Daily News

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

Michael O'Riordan

April 09, 2025

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

L.A. McKeown

April 03, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

News Conference News EHRA 2025

Sudden Cardiac Death Risk Linked to Long-term Antidepressant Use

Todd Neale

April 01, 2025

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes

Presenter: Marc P. Bonaca

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

News Daily News

The ‘Smoker’s Paradox’ Takes a New Hit From Long-term Analysis

Yael L. Maxwell

March 24, 2025

Advertisement

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

April 2025 Dispatch for the CV Team

AHA Statement Zeroes In On Sleep Health

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

Cardiotoxicity Rare With Common GI Chemotherapy

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Sudden Cardiac Death Risk Linked to Long-term Antidepressant Use

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

The ‘Smoker’s Paradox’ Takes a New Hit From Long-term Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content